Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
United States
University of California Irvine, Orange, California UC Davis Health, Sacramento, California Yale University, New Haven, Connecticut University of Florida Health, Gainesville, Florida Mayo Clinic, Jacksonville, Florida Emory University, Atlanta, Georgia Northwestern Memorial Hospital, Chicago, Illinois The University of Chicago Medical Center, Chicago, Illinois University of Kansas Medical Center, Kansas City, Kansas Tufts Medical Center, Boston, Massachusetts Massachusetts General Hospital, Boston, Massachusetts Boston Children's Hospital, Boston, Massachusetts Brigham and Women's Hospital, Boston, Massachusetts UMass Memorial Hospital, Worcester, Massachusetts University of Minnesota, Minneapolis, Minnesota Columbia University Irving Medical Center, New York, New York University of Rochester, Rochester, New York UNC Chapel Hill, Chapel Hill, North Carolina Children's Hospital of Philadelphia, Philadelphia, Pennsylvania Medical University of South Carolina, Charleston, South Carolina University of Texas MD Anderson Cancer Center, Houston, Texas Canada
Maisonneuve-Rosemont Hospital, Montreal, Quebec Spain
Clinica Universitaria de Navarra, Pamplona, Navarre